Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Haemonetics (HAZ) Stock Price & Analysis

1 Followers

HAZ Stock Chart & Stats

€109.00€2.00(1.87%)
At close: 5:30 PM GMT+1
€80€90€100€110Aug 17Aug 20Oct 8Oct 13
Day’s Range
EUR 109.00 - EUR 109.00
52-Week Range
EUR 43.20 - EUR 111.00
Previous Close
EUR 107.00
Volume
N/A
Average Volume (3M)
1
Market Cap
EUR 5.08B
Enterprise Value
EUR 5.76B
Total Cash (Recent Filing)
EUR 260.71M
Total Debt (Recent Filing)
EUR 1.12B
Price to Earnings (P/E)
54.2
Beta
-0.08
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
1.15
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Model

Haemonetics combines equipment placements with recurring proprietary disposable purchases, creating procedure-linked revenue after systems are installed. This razor-and-blades model can deepen customer retention, improve revenue visibility, and support durable growth as collection volumes and device utilization expand.

CSL Plasma Expansion

The expanded CSL relationship provides a multi-year pathway to enlarge Haemonetics’ installed base and recurring disposable revenue. Management expects converted centers to support future upgrades, while the stated potential for higher plasma volume could increase the long-term value of the platform.

Strong Cash Generation

Rapid improvement in operating and free cash flow strengthens Haemonetics’ ability to fund capacity expansion, product launches, debt repayment, and other strategic investments internally. Strong cash conversion also supports earnings quality and provides flexibility while the CSL rollout scales.

Bears Say

Higher Leverage

The increase in debt relative to equity raises financial risk and reduces flexibility if operating conditions weaken. Higher leverage can constrain capital allocation, increase sensitivity to interest costs, and make it harder to absorb execution issues during the company’s investment cycle.

Margin And Cost Pressure

Reduced margin expansion guidance indicates that higher operating expenses and ramp-related costs may absorb part of the benefit from revenue growth. Elevated personnel, freight, inflation, and investment costs could limit near-term earnings conversion even as gross demand remains healthy.

Plasma Volume Uncertainty

The company’s apheresis opportunity depends partly on collection activity controlled by plasma-center operators rather than Haemonetics. If collectors use Persona PLUS’s higher yield to reduce collection frequency, system utilization and disposable demand may grow more slowly than the installed-base opportunity suggests.

Haemonetics News

HAZ FAQ

What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was €43.20 and its highest was €111.00 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is €5.08B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 88 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on Nov 05, 2026. The company reported €1.22 earnings per share for the quarter, beating the consensus estimate of €1.167 by €0.053.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.15.
How many shares outstanding does Haemonetics have?
Haemonetics has 45,537,510 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of €1.22 in its last earnings report, beating expectations of €1.167. Following the earnings report the stock price went up 4.717%.
Which hedge fund is a major shareholder of Haemonetics?
Hedge funds hold Haemonetics shares: the largest hedge-fund position in Haemonetics is 1,223,423,086 shares, and hedge funds increased their holdings by 2.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology